about
Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosomeTherapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention.Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice.Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimbTherapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb.Autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the diabetic mouse hindlimb.Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hindlimb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways.Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress.Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders.Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma.CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy.Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic miceBeneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress.Multiple role of reactive oxygen species in the arterial wall.Involvement of Mediator complex in malignancy.Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic micec-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet.New insights in the transcriptional activity and coregulator molecules in the arterial wall.c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases.Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis.Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia.New trends in anti-atherosclerotic agents.New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder CancerNitric oxide and atherosclerosis: an update.Rethinking primary prevention of atherosclerosis-related diseases.Ex vivo behaviour of human bone tumor endothelial cellsDirected in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer.CXCR4 inhibitors: tumor vasculature and therapeutic challenges.Epigenetic regulators: Polycomb-miRNA circuits in cancer.Polycomb YY1 is a critical interface between epigenetic code and miRNA machinery after exposure to hypoxia in malignancy.Osteosarcoma cells induce endothelial cell proliferation during neo-angiogenesis.Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis.Expression of transcription factor Yin Yang 1 in human osteosarcomas.Pomegranate juice reduces oxidized low-density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cells.Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells.Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions.Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray.
P50
Q24324227-1E548A76-E3E3-4FA0-9255-EF29018334A4Q30910372-0425FD5D-F6DC-440D-8D9C-655B202FF3CDQ31046745-41D0FA07-BA73-4DB4-B905-62DA28DCF828Q33227147-FCDD1DE8-7DED-4F97-810F-EECB5489DD35Q33252182-B555B938-CF01-4818-84E5-4BC55E793959Q33266766-C57BF823-8CE8-4651-8441-0D7E6E4E9C0BQ33307935-7DD19AA5-32FC-43E6-A522-736E35C23674Q33935253-777ED8A9-F970-4E2C-8C4D-A4C9EA580D43Q33998697-A079F257-16FC-48C5-BEF5-96F6252E47EEQ34010668-BF13A41D-D780-4202-82A2-32523EBE375FQ34065323-F43208EB-0EAE-410C-8F68-AE0D7A1C90BDQ34069720-8BB02907-E3F2-47D6-B56A-AD629203C45FQ34156437-74AB2D47-E699-46E0-8EEE-5EA892679B8AQ34331467-987C7738-D93F-4774-B205-B5436891FD3BQ34334387-42D546EA-42FD-4ACD-AA32-160435C87FA0Q34392169-53D6AEE1-A954-48DB-9B1A-EFB4FBA73B9FQ34515736-7B494B0E-DFD1-47D8-8447-9159069446A3Q34623861-DDE77507-66CD-4D26-8164-504FB5A263F7Q34763602-83DA2727-4B16-4DCF-A466-227B5906A75FQ34990652-94C8757E-A992-47BA-9EB2-CA6A5FC45E23Q35173526-81F53CA6-F502-4B77-A5C9-1E03D9497058Q35203028-B46ACE9D-D5E0-43BC-8D3A-FDE91F95F64FQ35652254-E610441F-C0F1-4A54-AC93-D424102D9EDDQ36200279-ED22F4CB-63C9-489B-BB82-5A67EB239D25Q36226579-1F0163E8-C691-44F8-B26B-504FB4B224E4Q36473426-A2931C36-1540-4E3F-AC7D-6B9498F984FDQ36673698-82A1FEB7-A816-4E6F-851D-6A834CBEC080Q37061788-9AA381D7-6286-4AA3-B578-E35817C1063AQ37833570-A50FB6C3-9057-49F1-AF72-F31423C982EBQ37989227-11AA454C-5A06-4AE8-B4BA-3CAB2E653C40Q38774454-75E147CD-CB49-4556-9550-5ED94B04FD11Q38913818-B268DED9-9BA3-4B5D-A4FB-A72942F59192Q39264505-181D64EC-4A93-4DDC-8F2C-8F821B15A5D5Q40002560-D29F3134-6230-4869-85F7-9BF8D1B6628FQ40233961-AD2E6715-4539-4A05-A3AB-EEBD5A9315A9Q42489362-B524AC1A-8540-4754-A78D-CCD6CD898501Q42527191-B4ADF3AE-DA08-43D1-9EDE-DBEF3E249AA0Q43010737-F7E7A645-97B8-4DFA-BCDA-6E5B359CB685Q43823409-C3CCD899-ADA6-42FB-8C74-24A997CD3B5FQ43921907-6995B9E2-AC2A-4757-84B1-111D5ABA500E
P50
description
researcher ORCID ID = 0000-0002-2322-1557
@en
wetenschapper
@nl
name
Filomena de Nigris
@ast
Filomena de Nigris
@en
Filomena de Nigris
@es
Filomena de Nigris
@nl
type
label
Filomena de Nigris
@ast
Filomena de Nigris
@en
Filomena de Nigris
@es
Filomena de Nigris
@nl
prefLabel
Filomena de Nigris
@ast
Filomena de Nigris
@en
Filomena de Nigris
@es
Filomena de Nigris
@nl
P1153
7003919605
P31
P496
0000-0002-2322-1557